Aermony RespiClick is packaged in an advanced device to simplify the administration of inhaled therapy and reduce miscalculations by patients

image1

Teva Canada announces availability of Aermony RespiClick for bronchial asthma. (Credit: Teva Canada/Businesswire.)

Teva Pharmaceutical Industries’ subsidiary Teva Canada is commercialising its Aermony RespiClick (fluticasone propionate inhalation powder) for the maintenance treatment of steroid-responsive bronchial asthma.

Aermony RespiClick is offered as prophylactic therapy for patients aged 12 years and older, in a simple-to-use inhaler. The therapy is packaged in an advanced device to simplify the administration of inhaled therapy and reduce miscalculations by patients.

The drug delivery device features a cap that integrates the opening and priming steps, with a ‘click’ sound that confirms the dose is ready, to minimise patients’ coordination errors.

University of Toronto physician and researcher Anthony D’Urzo said: “Devices play a central role in the success of asthma therapy since the evidence clearly demonstrates an important association between inhaler errors and suboptimal asthma control.

“It stands to reason that a device that is simple to use may also minimize errors that may lead to poor asthma control. Aermony RespiClick has desirable ‘user-friendly’ features that make it a welcome addition for patients who require maintenance therapy with a medication like fluticasone propionate.”

Aermony RespiClick is offered in 55mcg, 113mcg, and 232mcg per actuation dose options

Teva is offering its device in three dose options, including 55mcg, 113mcg, and 232mcg per actuation, and is dosed as one inhalation twice daily, taken around 12 hours apart.

Teva Canada general manager Christine Poulin said: “We’re pleased that Aermony RespiClick is now available in Canada. With this innovative method of delivery of medication, respirologists and asthma patients will experience the simplified administration features the RespiClick device has to offer.

“Aermony RespiClick is a meaningful expansion of our offerings in respirology, which currently include both proprietary and generic products.”

Teva Canada is specialised in the development, production, and marketing of high-quality generic prescription pharmaceuticals. The company is focused on developing a diverse portfolio of advanced products in different therapeutic areas.